Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: An open-label, controlled, prospective study

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2744-2754

  Li, Xiang Yang ^a,b   Gao, Fen ^b   Li, Zhan Quan ^b   Guan, Wei ^b   Feng, Wei Li ^b   Ge, Ri Li ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b QINGHAI UNIVERSITY   (China)

Author keywords

healthy volunteers; high altitude; pharmacokinetics; sulfamethoxazole

Indexed keywords

HEPARIN; N4 ACETYLSULFAMETHOXAZOLE; SULFAMETHOXAZOLE;

ADULT; AGE DISTRIBUTION; ALTITUDE; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE MONITORING; BODY WEIGHT; CHINESE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PROTEIN BINDING; ELECTROCARDIOGRAM; ERYTHROCYTE; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; INDWELLING CATHETER; INTRAVENOUS CATHETER; LONG TERM EXPOSURE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NORMAL HUMAN; OPEN STUDY; PROSPECTIVE STUDY; RACE DIFFERENCE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; WEAKNESS;

ALTITUDE; ANOXIA; ANTI-INFECTIVE AGENTS; BIOTRANSFORMATION; BLOOD CHEMICAL ANALYSIS; BLOOD PROTEINS; CHINA; ERYTHROCYTES; HUMANS; MALE; PROSPECTIVE STUDIES; PROTEIN BINDING; SULFAMETHOXAZOLE; YOUNG ADULT;

EID: 74549189240     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.019     Document Type: Article

References (35)

1. Duplain H., Sartori C., and Scherrer U. High-altitude related illness [in French]. Rev Med Suisse. 3 (2007) 1766-1769
2. Mairbäurl H. Red blood cell function in hypoxia at altitude and exercise. Int J Sports Med. 15 (1994) 51-63
3. Sutton J.R., Reeves J.T., Wagner P.D., et al. Operation Everest II: Oxygen transport during exercise at extreme simulated altitude. J Appl Physiol. 64 (1988) 1309-1321
4. Heistad D.D., Abboud F.M., and Dickinson W. Richards lecture: Circulatory adjustments to hypoxia. Circulation 61 (1980) 463-470
5. Rowell L.B., Blackmon J.R., Kenny M.A., and Escourrou P. Splanchnic vasomotor and metabolic adjustments to hypoxia and exercise in humans. AmJ Physiol. 247 (1984) H251-H258
6. Wolff C.B. Cerebral blood flow and oxygen delivery at high altitude. High Alt Med Biol. 1 (2000) 33-38
7. Gallagher S.A., and Hackett P.H. High altitude illness. Emerg Med Clin North Am. 22 (2004) 329-355
8. Gallagher S.A., and Hackett P.H. High altitude illness. Emerg Med Clin North Am. 22 (2004) viii
9. Luks A.M., and Swenson E.R. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 133 (2008) 744-755
10. Aslam M., and Khan M.Z. The role of drugs in high altitude disorders. J Pak Med Assoc. 46 (1996) 90-92
11. Ritschel W.A., Paulos C., Arancibia A., et al. Pharmacokinetics of meperidine in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol. 36 (1996) 610-616
12. Ritschel W.A., Paulos C., Arancibia A., et al. Urinary excretion of meperidine and normeperedine in man upon acute and chronic exposure to high altitude. Methods Find Exp Clin Pharmacol. 18 (1996) 49-53
13. Arancibia A., Paulos C., Chávez J., and Ritschel W.A. Pharmacokinetics of lithium in healthy volunteers after exposure to high altitude. Int J Clin Pharmacol Ther. 41 (2003) 200-206
14. Ritschel W.A., Paulos C., Arancibia A., et al. Pharmacokinetics of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. J Clin Pharmacol. 38 (1998) 533-539
15. Ritschel W.A., Paulos C., Arancibia A., et al. Urinary excretion of acetazolamide in healthy volunteers after short- and long-term exposure to high altitude. Methods Find Exp Clin Pharmacol. 20 (1998) 133-137
16. Kamimori G.H., Eddington N.D., Hoyt R.W., et al. Effects of altitude (4300 m) on the pharmacokinetics of caffeine and cardio-green in humans. Eur J Clin Pharmacol. 48 (1995) 167-170
17. Masters P.A., O'Bryan T.A., Zurlo J., et al. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med. 163 (2003) 402-410
18. Bergan T., Ortengren B., and Westerlund D. Clinical pharmacokinetics of cotrimazine. Clin Pharmacokinet. 11 (1986) 372-386
19. Zhao L.Y., Shi X.G., Zhang Y.F., et al. Pharmacokinetic study of sulfamethoxazole and N4-acetylsulfamethoxazol. Chin J Clin Pharmacol. 17 (2001) 348-351
20. Jung T.R., Hwang S.W., Lee J.U., et al. Comparative consistency between obesity determination standards using body mass index and ideal body weight. J Korean Acad Fam Med. 22 (2001) 1765-1771
21. Ha Z., Zhu Y., Zhang X., et al. The effect of rhodiola and acetazolamide on the sleep architecture and blood oxygen saturation in men living at high altitude. Zhonghua Jie He He Hu Xi Za Zhi 25 (2002) 527-530
22. Chen Z.Y., Zheng Q.S., and Sun R.Y. Functions of the DAS software for pharmacologycal calculation. Chin J Clin Pharmacol Ther. 7 (2002) 562-564
23. Ritschel W.A. Binding of drugs to biological material. In: Ritschel W.A. (Ed). Handbook of Basic Pharmacokinetics-Including Clinical Applications. 4th ed. (1992), Drug Intelligence Publications, Hamilton, ll 153
24. Yu C.H. SPSS and Statistic Analysis. (2007), Publishing House of Electronics Industry, Beijing, China
25. State Food and Drug Administration of China. Technical guidelines of chemical drugs in clinical pharmacokinetics studies (2005). http://www.sda.gov.cn/gsz05106/07.pdf
26. Benet L.Z., Kroetz D.L., and Sheiner L.B. Pharmacokinetics: The dynamics of drug absorption, distribution, and elimination. In: Gilman A.G., Rall T.W., Nies A.S., and Taylor P. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. (1990), Pergamon Press, New York, NY
27. Surks M.I. Metabolism of human serum albumin in man during acute exposure to high altitude (14,100 feet). J Clin Invest. 45 (1966) 1442-1451
28. Imoberdorf R., Garlick P.J., McNurlan M.A., et al. Enhanced synthesis of albumin and fibrinogen at high altitude. J Appl Physiol. 90 (2001) 528-537
29. Maruyama K., Harada S., Nishigori H., and Iwatsuru M. Classification of drugs on the basis of bilirubin-displacing effect on human serum albumin. Chem Pharm Bull. 32 (1984) 2414-2420
30. Arancibia A., Gai M.N., Chávez J., et al. Pharmacokinetics of prednisolone in man during acute and chronic exposure to high altitude. Int J Clin Pharmacol Ther. 43 (2005) 85-91
31. Arancibia A., Nella Gai M., Paulos C., et al. Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers [published correction appears in Int J Clin Pharmacol Ther. 2004;42:526]. Int J Clin Pharmacol Ther. 42 (2004) 314-320
32. Reilly T.P., Woster P.M., and Svensson C.K. Methemoglobin formation by hydroxylamine metabolites of sulfamethoxazole and dapsone: Implications for differences in adverse drug reactions. J Pharmacol Exp Ther. 288 (1999) 951-959
33. Cribb A.E., Nakamura H., Grant D.M., et al. Role of polymorphic and monomorphic human arylamine N-acetyltransferases in determining sulfamethoxazole metabolism. Biochem Pharmacol. 45 (1993) 1277-1282
34. Jürgens G., Christensen H.R., Brøsen K., et al. Acute hypoxia and cytochrome P450-mediated hepatic drug metabolism in humans. Clin Pharmacol Ther. 71 (2002) 214-220
35. Streit M., Göggelmann C., Dehnert C., et al. Cytochrome P450 enzymemediated drug metabolism at exposure to acute hypoxia (corresponding to an altitude of 4,500 m). Eur J Clin Pharmacol. 61 (2005) 39-46